PH12022550079A1 - N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme - Google Patents

N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme

Info

Publication number
PH12022550079A1
PH12022550079A1 PH1/2022/550079A PH12022550079A PH12022550079A1 PH 12022550079 A1 PH12022550079 A1 PH 12022550079A1 PH 12022550079 A PH12022550079 A PH 12022550079A PH 12022550079 A1 PH12022550079 A1 PH 12022550079A1
Authority
PH
Philippines
Prior art keywords
enzyme
compounds
isoqc
fused
phenyl
Prior art date
Application number
PH1/2022/550079A
Other languages
English (en)
Inventor
Paul E Brennan
Bastiaan Evers
Original Assignee
Scenic Immunology B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scenic Immunology B V filed Critical Scenic Immunology B V
Publication of PH12022550079A1 publication Critical patent/PH12022550079A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
PH1/2022/550079A 2019-07-12 2020-07-10 N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme PH12022550079A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185997 2019-07-12
PCT/EP2020/069630 WO2021009068A1 (en) 2019-07-12 2020-07-10 N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme

Publications (1)

Publication Number Publication Date
PH12022550079A1 true PH12022550079A1 (en) 2023-04-12

Family

ID=67262155

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550079A PH12022550079A1 (en) 2019-07-12 2020-07-10 N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme

Country Status (12)

Country Link
US (1) US20230077723A1 (cg-RX-API-DMAC7.html)
EP (1) EP3997091A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022542540A (cg-RX-API-DMAC7.html)
KR (1) KR20220054293A (cg-RX-API-DMAC7.html)
CN (1) CN114466849B (cg-RX-API-DMAC7.html)
AU (1) AU2020312647A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000505A8 (cg-RX-API-DMAC7.html)
CA (1) CA3147154A1 (cg-RX-API-DMAC7.html)
IL (1) IL289784A (cg-RX-API-DMAC7.html)
MX (1) MX2022000521A (cg-RX-API-DMAC7.html)
PH (1) PH12022550079A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021009068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717089A3 (en) 2021-08-02 2026-06-24 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
AU2022203580A1 (en) * 2021-09-17 2023-04-06 Academia Sinica Methods of Increasing Cell Phagocytosis
EP4447682A1 (en) 2021-12-17 2024-10-23 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
PY2403614A (es) 2023-01-27 2025-09-11 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
PY2404467A (es) 2023-02-01 2025-03-31 Syngenta Crop Protection Ag Composiciones fungicidas
EP4455142A1 (en) 2023-04-26 2024-10-30 Scenic Immunology B.V. Novel inhibitor of qpctl and/or qc
PY2447478A (es) 2023-06-14 2025-03-18 Syngenta Crop Protection Ag Composiciones fungicidas
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
AR134999A1 (es) 2024-02-02 2026-05-20 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025224308A1 (en) * 2024-04-25 2025-10-30 Scenic Immunology B.V. Qpctl inhibitors
WO2026022173A1 (en) 2024-07-26 2026-01-29 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002106A (es) * 2008-09-04 2011-04-07 Probiodrug Ag Inhibidores novedosos.
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47

Also Published As

Publication number Publication date
EP3997091A1 (en) 2022-05-18
MX2022000521A (es) 2022-06-14
BR112022000505A2 (pt) 2022-03-22
BR112022000505A8 (pt) 2022-04-12
CN114466849A (zh) 2022-05-10
CN114466849B (zh) 2024-07-12
AU2020312647A1 (en) 2022-02-24
KR20220054293A (ko) 2022-05-02
WO2021009068A1 (en) 2021-01-21
US20230077723A1 (en) 2023-03-16
IL289784A (en) 2022-03-01
JP2022542540A (ja) 2022-10-05
CA3147154A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
MX2022000521A (es) Compuestos n-sustituidos-3,4-(5-anillo fusionado)-5-fenil-pirrolid in-2-ona como inhibidores de la enzima isoqc y/o qc.
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
ZA202403923B (en) Heterocyclic compounds as immunomodulators
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
MY209609A (en) Immunomodulators, compositions and methods thereof
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
AU2013311573A8 (en) Methods of treating Alzheimer's disease and pharmaceutical compositions thereof
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
PH12018501920B1 (en) Bromodomain inhibitors
MD20140082A2 (ro) Inhibitor al kinazei inductoare de apoptoză
MX2020012034A (es) Inhibidores de furina.
MX380928B (es) Inhibidores de kras g12c.
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
MX2017006447A (es) Agentes antifungicos.
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2021007425A (es) Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
MY197595A (en) Alkyl dihydroquinoline sulfonamide compounds